1
|
Vetvicka D, Suhaj P, Olejar T, Sivak L, Benes J, Pouckova P. Proteinase-activated Receptor 2: Springboard of Tumors. Anticancer Res 2024; 44:1-12. [PMID: 38159988 DOI: 10.21873/anticanres.16782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 11/23/2023] [Accepted: 11/28/2023] [Indexed: 01/03/2024]
Abstract
Proteinase-activated receptors (PARs) were discovered more than 25 years ago and since then, their role in cancer has been under investigation. Research has primarily focused on the receptors located on the membrane of cancer cells and their impact on metabolism, intracellular signalling, and proliferation. Regarding the host response to cancer, studies have predominantly examined the relationship of thrombin receptors (PAR-1, PAR-3, and PAR-4) with blood clotting in distant metastatic spread. However, limited studies have examined the role of PARs, especially PAR-2, in the host anti-tumor immunity. This review article provides insights into the role of PAR-2 on cancer cells and immune competent cells involved in cancer development and progression. It also discussed the current knowledge of the importance of PAR-2 activation at various stages of cancer progression and its association with cancer-related pain.
Collapse
Affiliation(s)
- David Vetvicka
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic;
| | - Petr Suhaj
- Department of Pathology and Molecular Medicine, Third Medical Faculty, Charles University and Thomayer University Hospital, Prague, Czech Republic
| | - Tomas Olejar
- Department of Pathology and Molecular Medicine, Third Medical Faculty, Charles University and Thomayer University Hospital, Prague, Czech Republic
| | - Ladislav Sivak
- Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic
| | - Jiri Benes
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Pavla Pouckova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
2
|
Hruby M, Martínez IIS, Stephan H, Pouckova P, Benes J, Stepanek P. Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers. Polymers (Basel) 2021; 13:3969. [PMID: 34833268 PMCID: PMC8618197 DOI: 10.3390/polym13223969] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 11/09/2021] [Accepted: 11/15/2021] [Indexed: 12/18/2022] Open
Abstract
Iron and copper are essential micronutrients needed for the proper function of every cell. However, in excessive amounts, these elements are toxic, as they may cause oxidative stress, resulting in damage to the liver and other organs. This may happen due to poisoning, as a side effect of thalassemia infusion therapy or due to hereditary diseases hemochromatosis or Wilson's disease. The current golden standard of therapy of iron and copper overload is the use of low-molecular-weight chelators of these elements. However, these agents suffer from severe side effects, are often expensive and possess unfavorable pharmacokinetics, thus limiting the usability of such therapy. The emerging concepts are polymer-supported iron- and copper-chelating therapeutics, either for parenteral or oral use, which shows vivid potential to keep the therapeutic efficacy of low-molecular-weight agents, while avoiding their drawbacks, especially their side effects. Critical evaluation of this new perspective polymer approach is the purpose of this review article.
Collapse
Affiliation(s)
- Martin Hruby
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic Heyrovského Náměstí 2, 162 06 Prague, Czech Republic;
| | - Irma Ivette Santana Martínez
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research Bautzner Landstraße 400, 01328 Dresden, Germany; (I.I.S.M.); (H.S.)
| | - Holger Stephan
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research Bautzner Landstraße 400, 01328 Dresden, Germany; (I.I.S.M.); (H.S.)
| | - Pavla Pouckova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Salmovska 1, 120 00 Prague, Czech Republic; (P.P.); (J.B.)
| | - Jiri Benes
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Salmovska 1, 120 00 Prague, Czech Republic; (P.P.); (J.B.)
| | - Petr Stepanek
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic Heyrovského Náměstí 2, 162 06 Prague, Czech Republic;
| |
Collapse
|
3
|
Albuquerque LJC, Sincari V, Jäger A, Kucka J, Humajova J, Pankrac J, Paral P, Heizer T, Janouškova O, Davidovich I, Talmon Y, Pouckova P, Štěpánek P, Sefc L, Hruby M, Giacomelli FC, Jäger E. pH-responsive polymersome-mediated delivery of doxorubicin into tumor sites enhances the therapeutic efficacy and reduces cardiotoxic effects. J Control Release 2021; 332:529-538. [PMID: 33716094 DOI: 10.1016/j.jconrel.2021.03.013] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 02/11/2021] [Accepted: 03/09/2021] [Indexed: 12/14/2022]
Abstract
The delivery of therapeutics into sites of action by using cargo-delivery platforms potentially minimizes their premature degradation and fast clearance from the bloodstream. Additionally, drug-loaded stimuli-responsive supramolecular assemblies can be produced to respond to the inherent features of tumor microenvironments, such as extracellular acidosis. We report in this framework the use of pH-responsive polymersomes (PSs) manufactured using poly([N-(2-hydroxypropyl)] methacrylamide)35-b-poly[2-(diisopropylamino)ethyl methacrylate]75 as the building unit (PHPMA35-b-PDPA75). The self-assemblies were produced with desired size towards long circulation time and tumor accumulation (hydrodynamic diameter - DH ~ 100 nm), and they could be successfully loaded with 10% w/w DOX (doxorubicin), while maintaining colloidal stability. The DOX loaded amount is presumably mainly burst-released at the acidic microenvironment of tumors thanks to the pH-switchable property of PDPA (pKa ~ 6.8), while reduced drug leakage has been monitored in pH 7.4. Compared to the administration of free DOX, the drug-loaded supramolecular structures greatly enhanced the therapeutic efficacy with effective growth inhibition of EL4 lymphoma tumor model and 100% survival rate in female C57BL/6 black mice over 40 days. The approach also led to reduced cardiotoxic effect. These features highlight the potential application of such nanotechnology-based treatment in a variety of cancer therapies where low local pH is commonly found, and emphasize PHPMA-based nanomedicines as an alternative to PEGylated formulations.
Collapse
Affiliation(s)
- Lindomar J C Albuquerque
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic; Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Avenida dos Estados 5001, Santo André 09210-580, Brazil.
| | - Vladimir Sincari
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic
| | - Alessandro Jäger
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic
| | - Jan Kucka
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic
| | - Jana Humajova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovska, 1, 120 00 Prague, Czech Republic
| | - Jan Pankrac
- Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Salmovská 3, Prague 2, 120 00, Czech Republic
| | - Petr Paral
- Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Salmovská 3, Prague 2, 120 00, Czech Republic
| | - Tomas Heizer
- Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Salmovská 3, Prague 2, 120 00, Czech Republic
| | - Olga Janouškova
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic
| | - Irina Davidovich
- Department of Chemical Engineering and the Russell Berrie Nanotechnology Institute (RBNI), Technion-Israel Institute of Technology, Haifa 3200003, Israel
| | - Yeshayahu Talmon
- Department of Chemical Engineering and the Russell Berrie Nanotechnology Institute (RBNI), Technion-Israel Institute of Technology, Haifa 3200003, Israel
| | - Pavla Pouckova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovska, 1, 120 00 Prague, Czech Republic
| | - Petr Štěpánek
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic
| | - Ludek Sefc
- Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Salmovská 3, Prague 2, 120 00, Czech Republic
| | - Martin Hruby
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic
| | - Fernando C Giacomelli
- Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Avenida dos Estados 5001, Santo André 09210-580, Brazil
| | - Eliézer Jäger
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovského nám. 2, 162 06 Prague 6, Czech Republic.
| |
Collapse
|
4
|
Jäger E, Sincari V, Albuquerque LJC, Jäger A, Humajova J, Kucka J, Pankrac J, Paral P, Heizer T, Janouskova O, Konefał R, Pavlova E, Sedlacek O, Giacomelli FC, Pouckova P, Sefc L, Stepanek P, Hruby M. Reactive Oxygen Species (ROS)-Responsive Polymersomes with Site-Specific Chemotherapeutic Delivery into Tumors via Spacer Design Chemistry. Biomacromolecules 2020; 21:1437-1449. [PMID: 32083473 DOI: 10.1021/acs.biomac.9b01748] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The lack of cellular and tissue specificities in conventional chemotherapies along with the generation of a complex tumor microenvironment (TME) limits the dosage of active agents that reaches tumor sites, thereby resulting in ineffective responses and side effects. Therefore, the development of selective TME-responsive nanomedicines is of due relevance toward successful chemotherapies, albeit challenging. In this framework, we have synthesized novel, ready-to-use ROS-responsive amphiphilic block copolymers (BCs) with two different spacer chemistry designs to connect a hydrophobic boronic ester-based ROS sensor to the polymer backbone. Hydrodynamic flow focusing nanoprecipitation microfluidics (MF) was used in the preparation of well-defined ROS-responsive PSs; these were further characterized by a combination of techniques [1H NMR, dynamic light scattering (DLS), static light scattering (SLS), transmission electron microscopy (TEM), and cryogenic TEM (cryo-TEM)]. The reaction with hydrogen peroxide releases an amphiphilic phenol or a hydrophilic carboxylic acid, which affects polymersome (PS) stability and cargo release. Therefore, the importance of the spacer chemistry in BC deprotection and PS stability and cargo release is herein highlighted. We have also evaluated the impact of spacer chemistry on the PS-specific release of the chemotherapeutic drug doxorubicin (DOX) into tumors in vitro and in vivo. We demonstrate that by spacer chemistry design one can enhance the efficacy of DOX treatments (decrease in tumor growth and prolonged animal survival) in mice bearing EL4 T cell lymphoma. Side effects (weight loss and cardiotoxicity) were also reduced compared to free DOX administration, highlighting the potential of the well-defined ROS-responsive PSs as TME-selective nanomedicines. The PSs could also find applications in other environments with high ROS levels, such as chronic inflammations, aging, diabetes, cardiovascular diseases, and obesity.
Collapse
Affiliation(s)
- Eliézer Jäger
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Vladimir Sincari
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Lindomar J C Albuquerque
- Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Avenida dos Estados 5001, Santo André 09210-580, Brazil
| | - Alessandro Jäger
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Jana Humajova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Salmovska 1, 120 00 Prague, Czech Republic
| | - Jan Kucka
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Jan Pankrac
- Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Salmovská 3, Prague 2, 120 00 Prague, Czech Republic
| | - Petr Paral
- Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Salmovská 3, Prague 2, 120 00 Prague, Czech Republic
| | - Tomas Heizer
- Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Salmovská 3, Prague 2, 120 00 Prague, Czech Republic
| | - Olga Janouskova
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Rafał Konefał
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Ewa Pavlova
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Ondrej Sedlacek
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Fernando C Giacomelli
- Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Avenida dos Estados 5001, Santo André 09210-580, Brazil
| | - Pavla Pouckova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Salmovska 1, 120 00 Prague, Czech Republic
| | - Ludek Sefc
- Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Salmovská 3, Prague 2, 120 00 Prague, Czech Republic
| | - Petr Stepanek
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| | - Martin Hruby
- Institute of Macromolecular Chemistry, Heyrovsky Sq. 2, 162 06 Prague, Czech Republic
| |
Collapse
|
5
|
Olejar T, Vetvicka D, Boucek J, Zabrodsky M, Benes J, Kabesova M, Pouckova P. The FSHR Expression in Head and Neck Squamous Cell Cancer. A Pilot Immunohistochemical Study. Anticancer Res 2020; 40:349-356. [PMID: 31892586 DOI: 10.21873/anticanres.13959] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 12/01/2019] [Accepted: 12/02/2019] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Follicle-stimulating hormone receptor (FSHr), expressed on endothelial cells of vessels in different malignant tumors, has been recently investigated as a potential pan-receptor of cancer treatment. However, the expression of this receptor has also been confirmed in other tissues under pathological conditions including cancer. The aim of the presented pilot study was to evaluate the expression of FSHr in head and neck squamous cancer (HNSCC). PATIENTS AND METHODS A total of 28 HNSCC patient samples were immunohistochemically analyzed for the presence of FSHr using a commercially available primary antibody. RESULTS FSHr was detected not only in the tumor tissue, but also in the basal layer or dysplastic parts of squamous mucosa and also in fibroblasts surrounding the tumor tissue. CONCLUSION FSHr is present on different benign or malignant mesenchymal and epithelial structures in HNSCC. A brief literature review revealed a wider role of FSHr in the development of neoplasia.
Collapse
Affiliation(s)
- Tomas Olejar
- Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.,Institute of Pathology and Molecular Medicine, Thomayer Memorial Hospital in Prague and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
| | - David Vetvicka
- Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Jan Boucek
- Department of Otorhinolaryngology Head and Neck Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Michal Zabrodsky
- Department of Otorhinolaryngology Head and Neck Surgery, First Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - Jiri Benes
- Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Martina Kabesova
- Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Pavla Pouckova
- Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
6
|
Zeman J, Benes J, Pouckova P, Zadinova M, Lukes P. Effect of shock waves combined with cytostatics on the growths of tumors in vivo. Physiol Res 2019; 68:S475-S481. [PMID: 32118479 DOI: 10.33549/physiolres.934386] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Based on their field of application, the physical parameters of shock waves differ. Experiments referred to in this article used tandem shock waves generated on the surface of a composite anode. There, individual pores of the anode produce multichannel discharges. The composite anode may have a variety of shapes, which, consequently, influence the arrangement of the entire apparatus and the area of their application. Experiments referred to in this article utilise an anode divided into two parts that generated tandem shock waves. The previously conducted experiments have clearly shown that the effect of a tandem shock wave can be very well localized in the focal area, causing necrosis and apoptosis of the tumor cells, and enhancing the effect of cytostatics. This study investigated the effect of tandem shock waves with concomitantly administered cytostatics. We conducted our experiments on Lewis rats. The rats were injected with syngeneic sarcoma tumor cells intradermally and caudally on both the right and left sides. The highest rate of tumor growth inhibition was observed in the cisplatin-treated group that was subsequently treated with shock waves. The effect of shock waves on cell membranes is well described as they increase their permeability due to sonodynamic effect induced by cavitation. The results of experiments referred to in this article conducted in vivo in experimental animals enable us to note that the shock wave increases the effect of chemotherapy administered.
Collapse
Affiliation(s)
- J Zeman
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic.
| | | | | | | | | |
Collapse
|
7
|
Rak J, Pouckova P, Benes J, Vetvicka D. Drug Delivery Systems for Phthalocyanines for Photodynamic Therapy. Anticancer Res 2019; 39:3323-3339. [PMID: 31262853 DOI: 10.21873/anticanres.13475] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Revised: 03/28/2019] [Accepted: 03/29/2019] [Indexed: 11/10/2022]
Abstract
The focus of this review is to describe the state-of-art in the development of innovative drug delivery systems for phthalocyanines as photosensitizers for photodynamic therapy (PDT). PDT is a medical treatment combining photosensitizers (PSs) activated by visible light of a specific wavelength to selectively destroy targeted cells, tumor tissues and its surrounding vasculature. In the last decades, PDT has been under intense investigation, first as a promising alternative approach for improved cancer treatment, later against microbial infection and nowadays, mainly in aesthetic medicine, against age-related degeneration. The success of PDT is restricted because of difficulties with administration and skin permeation of PSs. As PDT importance raises, there is high interest for advanced formulations and delivery systems (DDS) for PS, especially formulations based on nanotechnology. Accordingly, this review deals with the innovations pertaining to DDS for PDT as disclosed in recent patents and literature.
Collapse
Affiliation(s)
- Jakub Rak
- National Institute of Mental Health, Klecany, Czech Republic.,Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Pavla Pouckova
- Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Jiri Benes
- Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - David Vetvicka
- Institute of Biophysics and Informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
8
|
Mistrik M, Skrott Z, Hajduch M, Friis S, Dzubak P, Gursky J, Majera D, Ozdian T, Vaclavkova J, Michalova M, Pouckova P, Cvek B, Andersen KK, Bartek J. Abstract LB-264: Alcohol-aversion drug disulfiram targets cancer via p97 segregase adaptor NPL4. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-lb-264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer incidence is rising and this global challenge is further exacerbated by resistance of advanced tumors to standard-of-care and emerging precision medicines. A promising approach to such unmet need for innovative and cost-effective cancer treatments is drug repurposing, exploitation of drugs already approved for other indications that show anticancer activity. Here we highlight the potential for repurposing disulfiram (Antabuse), an old alcohol-aversion drug that kills a broad range of cancer types in preclinical studies. Our nationwide population study reveals that patients who continued using disulfiram have a lower risk of death from cancer compared to those who stopped using the drug at their diagnosis. More importantly, we identify ditiocarb-copper complex as the metabolite of disulfiram responsible for anticancer effects, present methods to detect its preferential accumulation in tumors and candidate biomarkers of impact in cells and tissues. Finally, our functional and biophysical analyses reveal the long-thought molecular target: NPL4 adapter of the p97/VCP segregase essential for protein recycling involved in multiple stress-response cellular pathways.
Citation Format: Martin Mistrik, Zdenek Skrott, Marian Hajduch, Søren Friis, Petr Dzubak, Jan Gursky, Dusana Majera, Tomas Ozdian, Jana Vaclavkova, Martina Michalova, Pavla Pouckova, Boris Cvek, Klaus Kaae Andersen, Jiři Bartek. Alcohol-aversion drug disulfiram targets cancer via p97 segregase adaptor NPL4 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-264.
Collapse
Affiliation(s)
- Martin Mistrik
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Zdenek Skrott
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Marian Hajduch
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Søren Friis
- 2Danish Cancer Society Research Center, Copenhagen, Denmark
| | - Petr Dzubak
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Jan Gursky
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Dusana Majera
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Tomas Ozdian
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Jana Vaclavkova
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Martina Michalova
- 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky Univ., Olomouc, Czech Republic
| | - Pavla Pouckova
- 3Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Boris Cvek
- 4Olomouc University Social Health Institute, Palacky University, Olomouc, Czech Republic
| | | | - Jiři Bartek
- 2Danish Cancer Society Research Center, Copenhagen, Denmark
| |
Collapse
|
9
|
Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Dzubak P, Vrobel I, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou QP, Olsen J, Hajduch M, Cvek B, Deshaies RJ, Bartek J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 2017; 552:194-199. [PMID: 29211715 PMCID: PMC5730499 DOI: 10.1038/nature25016] [Citation(s) in RCA: 457] [Impact Index Per Article: 65.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Accepted: 11/08/2017] [Indexed: 12/21/2022]
Abstract
Cancer incidence is rising and this global challenge is further exacerbated by tumour resistance to available medicines. A promising approach to such unmet need for improved cancer treatment is drug repurposing. Here we highlight the potential for repurposing disulfiram (Antabuse), an old alcohol-aversion drug effective against diverse cancer types in preclinical studies. Our nationwide epidemiological study reveals that patients who continuously used disulfiram have a lower risk of death from cancer compared to those who stopped using the drug at their diagnosis. Moreover, we identify ditiocarb-copper complex as the metabolite of disulfiram responsible for anticancer effects, and provide methods to detect its preferential accumulation in tumours and candidate biomarkers for impact in cells and tissues. Finally, our functional and biophysical analyses reveal the long-sought molecular target of disulfiram’s tumour suppressing effects as NPL4, an adapter of p97/VCP segregase essential for protein turnover involved in multiple regulatory and stress-response cellular pathways.
Collapse
Affiliation(s)
- Zdenek Skrott
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Martin Mistrik
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | | | - Søren Friis
- Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark
| | - Dusana Majera
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Jan Gursky
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Tomas Ozdian
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Jirina Bartkova
- Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.,Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - Zsofia Turi
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Pavel Moudry
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Marianne Kraus
- Kantonsspital St Gallen, Department Oncology/Hematology, St Gallen, Switzerland
| | - Martina Michalova
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Jana Vaclavkova
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Petr Dzubak
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Ivo Vrobel
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Pavla Pouckova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, 120 00 Prague 2, Czech Republic
| | - Jindrich Sedlacek
- Department of Cell Biology & Genetics, Palacky University, Olomouc, Czech Republic
| | | | - Anne Kutt
- Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark
| | - Jing Li
- Division of Biology and Biological Engineering, Caltech, Pasadena, California 91125, USA
| | - Jana Mattova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, 120 00 Prague 2, Czech Republic
| | - Christoph Driessen
- Kantonsspital St Gallen, Department Oncology/Hematology, St Gallen, Switzerland
| | - Q Ping Dou
- Barbara Ann Karmanos Cancer Institute and Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan, USA.,School of Basic Medical Sciences, Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou 511436, China
| | - Jørgen Olsen
- Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark
| | - Marian Hajduch
- Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
| | - Boris Cvek
- Department of Cell Biology & Genetics, Palacky University, Olomouc, Czech Republic
| | - Raymond J Deshaies
- Division of Biology and Biological Engineering, Caltech, Pasadena, California 91125, USA.,Howard Hughes Medical Institute, Caltech, Pasadena, California 91125, USA
| | - Jiri Bartek
- Danish Cancer Society Research Center, DK-2100 Copenhagen, Denmark.,Science for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| |
Collapse
|
10
|
Vetrik M, Mattova J, Kucka J, Mackova H, Sedlacek O, Pouckova P, Policianova O, Brus J, Eigner S, Sevc L, Stepanek P, Hruby M. New treatment of Wilson´s disease. J Control Release 2017. [DOI: 10.1016/j.jconrel.2017.03.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Sedlacek O, Kucka J, Mattova J, Parizek M, Studenovsky M, Zadinova M, Pouckova P, Hruby M. Multistage-targeted pH-responsive polymer conjugate of Auger electron emitter: Optimized design and in vivo activity. Eur J Pharm Sci 2014; 63:216-25. [DOI: 10.1016/j.ejps.2014.07.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Revised: 07/17/2014] [Accepted: 07/31/2014] [Indexed: 12/31/2022]
|
12
|
Vetvicka D, Zadinova M, Nekvasil M, Jezek P, Rakusan J, Karaskova M, Kralova J, Kral V, Pouckova P. 754: Experimental topical photodynamic therapy of various carcinomas. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50662-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Olejar T, Vetvicka D, Zadinova M, Pouckova P, Kukal J, Jezek P, Matej R. Dual role of host Par2 in a murine model of spontaneous metastatic B16 melanoma. Anticancer Res 2014; 34:3511-3515. [PMID: 24982362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM We investigated differences of metastatic spread of normal proteinase-activated receptor-2 (Par2+/+) melanoma B16 in Par2-/- (knock-out) animals compared to C57Bl6 mice. MATERIALS AND METHODS Nine knock-out mice B6.Cg-F2rl1tm1Mslb/J (Par2-/-) and nine C57Bl6/J controls were subcutaneously inoculated with B16 melanoma tissue cells. Twelve days after inoculation, all primary tumors were removed. Survival and metastatic spread was followed for up to 100 days after primary tumor extirpation. RESULTS Excised primary tumors were on average larger in Par2-/- mice (360 mm3 vs. 221 mm3 in C57Bl6/J). Distant spontaneous metastases developed in only 3 of 9 of Par2-/- mice in comparison to 6 of 9 controls. The average survival time was 84 days in Par2-/- animals compared to 63 days in C57Bl6/J mice. CONCLUSION Host Par2 melanoma model contributes to the limitation of local cancer progression in one area, while on the other hand is important for enhancing distant metastatic spread.
Collapse
Affiliation(s)
- Tomas Olejar
- Department of Pathology and Molecular Medicine, Thomayer Hospital, Prague, Czech Republic Department No. 75, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - David Vetvicka
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic CancerTech s.r.o., Pruhonek, Prague, Czech Republic
| | - Marie Zadinova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - Pavla Pouckova
- Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - Jaromir Kukal
- Department of Software Engineering, Faculty of Nuclear Science and Physical Engineering, Czech Technical University, Prague, Czech Republic
| | - Petr Jezek
- Department No. 75, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - Radoslav Matej
- Department of Pathology and Molecular Medicine, Thomayer Hospital, Prague, Czech Republic Department of Pathology, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| |
Collapse
|
14
|
Mattova J, Pouckova P, Zadinova M, Benes J, Nekvasil M, Jezek P, Rakusan J, Karaskova M, Kralova J, Kral V, Vetvicka D. Experimental Topical Photodynamic Therapy of Tongue and Colon Carcinoma. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt203.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Sutoris K, Rakusan J, Karaskova M, Mattova J, Benes J, Nekvasil M, Jezek P, Zadinova M, Pouckova P, Vetvicka D. Novel topical photodynamic therapy of prostate carcinoma using hydroxy-aluminum phthalocyanine entrapped in liposomes. Anticancer Res 2013; 33:1563-1568. [PMID: 23564798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND Clinically-approved anticancer photodynamic therapy (PDT) is now extensively studied for various cancer diagnoses. We focused on the treatment efficacy of topical administration of hydroxy-aluminum phthalocyanine (AlOH-PC) entrapped in liposomes against in vivo models of prostate carcinomas. MATERIALS AND METHODS LNCaP and PC3 cells were subcutaneously injected into the right flank of athymic nude mice. Mice with grown tumours were used for in vivo efficacy studies. Firstly, we applied different doses of AlOH-PC to less aggressive LNCaP tumours to determine the effective dose. In later studies, we focused on more aggressive prostate tumours (PC3) using doses of liposomal-AlOH-PC gel formulation. Topical application of photosensitizers was followed by PDT irradiation (600-700 nm, 635 nm peak). Tumour growth was measured three times-a-week. RESULTS Comparison of PDT of aggressive PC3 and less aggressive LNCaP prostate carcinomas showed that both tumour types are sensitive and treatable by liposomal formulation of AlOH-PC. For LNCaP tumours the efficient dose (100% experimental animals cured, n=8/8) was 4.5 mg/ml of AlOH-PC in the gel. Whereas, in the case of PC3 carcinomas, a dose of 4 mg/ml significantly postponed tumour growth, but no animals were cured (n=0/8); a sufficient curative dose (100% mice cured, n=8/8) was 6 mg/ml of AlOH-PC in the gel. CONCLUSION Liposomal AlOH-PC gel has potential for effective PDT of prostate carcinomas.
Collapse
Affiliation(s)
- Karol Sutoris
- Charles University in Prague, Third Faculty of Medicine, Prague, Czech Republic.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Sutoris K, Vetvicka D, Horak L, Benes J, Nekvasil M, Jezek P, Zadinova M, Pouckova P. Evaluation of topical photodynamic therapy of mammary carcinoma with an experimental gel containing liposomal hydroxyl-aluminium phthalocyanine. Anticancer Res 2012; 32:3769-3774. [PMID: 22993318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Photodynamic therapy (PDT) is a clinically-accepted approach for the therapy of many types of cancer. This study focused on the treatment of mammarian carcinoma by topical administration of hydroxyl-aluminium phthalocyanine (AlOH-PC), compared to a clinically-approved photosensitizer (Metvix, Galderma & PhotoCure ASA, Inc., Oslo, Norway). MATERIALS AND METHODS MDA-MB 231 cells were subcutaneously injected into the right flank of athymic nude mice. Mice with grown tumours were used for in vivo efficacy studies. Different doses of liposomal AlOH-PC were applied to determine the most effective dose. In later studies, Metvix or our liposomal-AlOH-PC gel formula were used. Topical application of photosensitizers was followed by the PDT irradiation at 600-700 nm (635 nm peak). Tumour growth was measured three times weekly. RESULTS Therapeutic studies revealed that AlOH-PC treatment led to complete tumour remission in 90% (9/10) of experimental animals, whereas usage of the commercially available Metvix only postponed the tumour growth. Moreover, usage of liposomal AlOH-PC shortened the time allowed between the application of the photosensitizer and light exposure: for Metvix, hours are usually needed, while the tested liposomal AlOH-PC showed remarkable outcomes after only 10 min. CONCLUSION Liposomal AlOH-PC gel appears to be potentially suitable for PDT of mammarian carcinoma.
Collapse
Affiliation(s)
- Karol Sutoris
- Clinic of Surgery, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Benes J, Zeman J, Pouckova P, Zadinova M, Sunka P, Lukes P. Biological effects of tandem shock waves demonstrated on magnetic resonance. ACTA ACUST UNITED AC 2012; 113:335-8. [DOI: 10.4149/bll_2012_076] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
18
|
Matousek J, Podzimek T, Pouckova P, Stehlik J, Skvor J, Lipovova P, Matousek J. Antitumor activity of apoptotic nuclease TBN1 from L. esculentum. Neoplasma 2010; 57:339-48. [PMID: 20429625 DOI: 10.4149/neo_2010_04_339] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Nuclease from tomato (TBN1) was produced by in planta biotechnology purified and tested for its anticarcinogenic properties. The nuclease was cytostatic after its intratumoral administration to nude mice bearing human melanoma or prostate carcinoma or after tumor targeting by TBN1 administration intravenously as conjugate with polyethylene glycol (PEG). Inhibitory effects of TBN1 on tumor growth were comparable to effects of bovine seminal RNase (BS-RNase), but the inhibition was reached at about ten times lower protein concentration. Simultaneously, TBN1 exhibited a lower degree of embryotoxicity compared to BS-RNAse and other nucleases. TBN1 showed significant stability in vivo, because it was readily detected after its administration intratumorally or intravenously by the fluorescence methods. Intravenous administration of TBN1-PEG caused significant inhibition of tumor proliferation without obvious degenerative changes, while direct administration of TBN1 into melanoma tumors led to rapid tumor tissue degeneration. The fact can be essential for the mode of TBN1 biological action that mature nuclease is a small (36 kDa) thermostable glycoprotein that has ability to destroy human 28S, 18S, 7S and 5.8S RNA, circular RNAs, double-stranded RNA in vitro and shows DNase and 3'nucleotidase activities.
Collapse
Affiliation(s)
- J Matousek
- Biology Centre, Academy of Sciences of the Czech Republic v.v.i., Institute of Plant Molecular Biology, Czech Republic
| | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Colorectal cancer is one of the most common cancers in Europe and North America and it is the most common gastrointestinal carcinoma. The population in the Czech Republic has a higher incidence of colorectal carcinoma compared to other countries. Efforts are underway to develop better screening strategies and novel therapies to improve patient survival rates. Despite all efforts, colorectal cancer remains one of the leading causes of death from cancer. Photodynamic therapy (PDT) is an established modality for the treatment of various diseases. The PDT procedure involves the administration of a photosensitizer followed by illumination. The anti-tumor effects result from direct killing of malignant cells, shutting down of the tumor's vasculature, and the promotion of an immune response. In our experiment, we examined the effects of phototherapy with disulfonated hydroxyaluminum phthalocyanine (Al(OH)S2Pc) on the growth of colorectal carcinoma cells, in an effort to offer a new treatment modality for patients with this disease.
Collapse
Affiliation(s)
- Jan Stukavec
- Third Faculty of Medicine, Clinic of Surgery, Charles University, Prague, Czech Republic.
| | | | | | | |
Collapse
|
20
|
Lipovova P, Podzimek T, Orctova L, Matousek J, Pouckova P, Soucek J, Matousek J. Antitumor and biological effects of black pine (pinus nigra) pollen nuclease. Neoplasma 2008; 55:158-164. [PMID: 18237255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The antitumor effect of black pine (Pinus nigra) pollen nuclease (PN) tested in vitro was negligible in comparison with bovine seminal ribonuclease (BS-RNase). However, in the experiments in vivo a significant decrease of the human melanoma tumor size was observed in the mice treated with this nuclease and also with the animal RNases and DNase I. In nude mice injected intratumoraly with PN (10 microg/dose) the tumor size decreased from 100% in the control mice to 46% in treated mice whereas in counterparts treated with BS-RNase and DNase I the tumor growth was reduced a little more, however after ten times higher doses (100 and 80 microg per dose). Certain aspermatogenic and embryotoxic activity as an expression of side effects of PN and comparative enzymes also appeared, but it was lower compared to the effect of bovine seminal ribonuclease. Immunogenicity of PN was significantly weaker in comparison with BS-RNase. The antibodies against black pine nuclease produced in the injected mice did not inactivate the biological effects of this plant nuclease in vivo. In conclusion PN nuclease proved in vivo higher antitumor activity against human melanoma tumors growing in athymic mice in comparison with animal bovine seminal ribonuclease and DNase I.
Collapse
Affiliation(s)
- P Lipovova
- Department of Biochemistry and Microbiology, Institute of Chemical Technology Prague, Prague, Czech Republic
| | | | | | | | | | | | | |
Collapse
|
21
|
Stukavec J, Horak L, Duchac V, Jirasek T, Rakusan J, Karaskova M, Pouckova P. Comparison of photodynamic therapy with phthalocyanine and photofrin in human colorectal carcinoma. Neoplasma 2008; 55:127-129. [PMID: 18237250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Photodynamic therapy (PDT) has been developed in recent years as a new modality for the treatment of various neoplastic and non-neoplastic lesions. Although the method of combining light with photosensitizers for treatment has been around for a century, further understanding has been evolved over the past decades. The method is based on the phenomenon involving the combination of photosensitizer and light. Neither drug nor light alone are effective as therapeutic agents. The antitumour effects result from direct cell damage, destruction of tumor vasculature and activation of a nonspecific immune response. The more accepted use of PDT is still restricted for ophthalmology, dermatology and treatment of some stages of esophageal, lung and urinary bladder cancer. In our experiments, the effect of phototherapy with disulfonated hydroxyaluminium phthalocyanine (Al(OH)S2Pc) and photofrin (control group) on the growth of human colorectal carcinoma on nude mice was studied. We chose colorectal carcinoma, because the Czech population has the highest incidence and it is still increasing. We try to offer a new possibility of treatment for patients with this severe disease.
Collapse
Affiliation(s)
- J Stukavec
- Clinic of Surgery, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
| | | | | | | | | | | | | |
Collapse
|
22
|
Stukavec J, Horak L, Duchac V, Pouckova P, Jirasek T. 62 POSTER Experimental photodynamic therapy with phthalocyanine, a new possibility of treatment of colorectal carcinoma. Eur J Surg Oncol 2006. [DOI: 10.1016/s0748-7983(06)70497-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
23
|
Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M. Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs 2006; 17:201-6. [PMID: 16428939 DOI: 10.1097/00001813-200602000-00012] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The oral anti-tumor activity of a novel platinum(IV) complex, coded as LA-12, with a bulky adamantylamine ligand was evaluated and compared with another platinum(IV) complex satraplatin. The human carcinoma xenografts of colon HCT116, prostate PC3, and ovarian A2780 and A2780/cisR (resistant to cisplatin) were used to evaluate the in-vivo anti-tumor activity. The daily x 5 repeated dose regimen in equimolar doses of LA-12 and satraplatin, administered in 2 cycles, was selected for this evaluation. All doses of LA-12 and satraplatin were significantly effective in comparison with the control. The activities of LA-12 in all doses and all used tumor xenografts were higher than equimolar doses of satraplatin. The highest effect was reached with LA-12 at a dose of 60 mg/kg. The shapes of growth curves of ovarian carcinoma A2780 and its subline resistant to cisplatin after therapy with LA-12 were very similar. This shows that LA-12 is able to overcome resistance to cisplatin.
Collapse
Affiliation(s)
- Petr Sova
- Research and Development, PLIVA-Lachema a.s., Brno, Czech Republic.
| | | | | | | | | | | |
Collapse
|
24
|
Pouckova P, Skvor J, Gotte G, Vottariello F, Slavik JT, Matousek J, Laurents DV, Libonati M, Soucek J. Some biological actions of PEG-conjugated RNase A oligomers. Neoplasma 2006; 53:79-85. [PMID: 16416018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Previously we have shown that monomeric RNase A has no significant biological activity, whereas its oligomers (dimer to tetramer) prepared by lyophilizing from 50% acetic acid solutions, show remarkable aspermatogenic and antitumor activities. Furthermore, conjugates prepared by chemical binding of native RNase A to polyethylene glycol (PEG) have shown a significant aspermatogenic and antitumor activities. In this work we show that the chemical conjugation of PEG to the RNase A C-dimer, and to the two RNase A trimers (NC-trimer and C- trimer) decreases the aspermatogenic activity of the oligomers while increasing their inhibitory activity on the growth of the human UB900518 amelanotic melanoma transplanted in athymic nude mice. Moreover, the PEG-conjugated RNaseA oligomers are devoid, like the free oligomers, of any embryotoxic activity.
Collapse
Affiliation(s)
- P Pouckova
- Institute of Hematology and Blood Transfusion, 12820 Prague, Czech Republic
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kralova J, Synytsya A, Pouckova P, Koc M, Dvorak M, Kral V. Novel Porphyrin Conjugates with a Potent Photodynamic Antitumor Effect: Differential Efficacy of Mono- and Bis-β-cyclodextrin Derivatives In Vitro and In Vivo. Photochem Photobiol 2006; 82:432-8. [PMID: 16613522 DOI: 10.1562/2005-05-06-ra-516] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In the present study we investigated the photosensitizing properties of two novel mono- and bis-cyclodextrin tetrakis (pentafluorophenyl) porphyrin derivatives in several tumor cell lines and in BALB/c mice bearing subcutaneously transplanted syngeneic mouse mammary carcinoma 4T1. Both studied sensitizers were localized mainly in lysosomes and were found to induce cell death by triggering apoptosis in human leukemic cells HL-60. In 4T1 and other cell lines both apoptotic and necrotic modes of cell death occurred depending on drug and light doses. Mono-cyclodextrin porphyrin derivative P(beta-CD)1 exhibited stronger in vitro phototoxic effect than bis-cyclodextrin derivative P(beta-CD)2. However, in vivo P(beta-CD)2 displayed faster tumor uptake with maximal accumulation 6 h after application, leading to complete and prolonged elimination of subcutaneous tumors within 3 days after irradiation (100 J cm(-2)). In contrast, P(beta-CD)1 uptake was slower (48 h) and the reduction of tumor mass was only transient, reaching the maximum at the 12 h interval when a favorable tumor-to-skin ratio appeared. Thus, P(beta-CD)2 represents a new photosensitizing drug displaying fast and selective tumor uptake, strong antitumor activity and fast elimination from the body.
Collapse
Affiliation(s)
- Jarmila Kralova
- Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
A novel anti-tumor platinum(IV) complex, coded as LA-12, with a bulky adamantylamine ligand displaying oral activity was prepared and its oral activity was evaluated. The murine ADJ/PC6 plasmacytoma and human A2780 ovarian carcinoma tumor model were used to evaluate the in vivo anti-tumor activity of a single dose and also of repeated doses with comparison to the activity of cisplatin and of the platinum(IV) complex satraplatin. The acute toxicity of LA-12 in mice is relatively low (maximum tolerated dose 1000 mg/kg), and the effective dose is comparable to that of cisplatin and higher than that of satraplatin. The therapeutic index derived from this is very high (250). In the human tumor model, two repeated dose schedule regimens were evaluated. LA-12 exerted a significantly higher anti-tumor activity than other substances, i.e. cisplatin and satraplatin, in repeated doses on the murine ADJ/PC6 plasmacytoma tumor model. The dailyx5 repeated dose regimen was selected for further evaluation.
Collapse
Affiliation(s)
- Petr Sova
- Research and Development, PLIVA-Lachema, Brno, Czech Republic.
| | | | | | | | | | | |
Collapse
|
27
|
Matousek J, Gotte G, Pouckova P, Soucek J, Slavik T, Vottariello F, Libonati M. Antitumor activity and other biological actions of oligomers of ribonuclease A. J Biol Chem 2003; 278:23817-22. [PMID: 12697760 DOI: 10.1074/jbc.m302711200] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Dimers, trimers, and tetramers of bovine ribonuclease A, obtained by lyophilization of the enzyme from 40% acetic acid solutions, were purified and isolated by cation exchange chromatography. The two conformers constituting each aggregated species were assayed for their antitumor, aspermatogenic, or embryotoxic activities in comparison with monomeric RNase A and bovine seminal RNase, which is dimeric in nature. The antitumor action was tested in vitro on ML-2 (human myeloid leukemia) and HL-60 (human myeloid cell line) cells and in vivo on the growth of human non-pigmented melanoma (line UB900518) transplanted subcutaneously in nude mice. RNase A oligomers display a definite antitumor activity that increases as a function of the size of the oligomers. On ML-2 and HL-60 cells, dimers and trimers generally show a lower activity than bovine seminal RNase; the activity of tetramers, instead, is similar to or higher than that of the seminal enzyme. The growth of human melanoma in nude mice is inhibited by RNase A oligomers in the order dimers < trimers < tetramers. The action of the two tetramers is very strong, blocking almost completely the growth of melanoma. RNase A dimers, trimers, and tetramers display aspermatogenic effects similar to those of bovine seminal RNase, but, contrarily, they do not show any embryotoxic activity.
Collapse
Affiliation(s)
- Josef Matousek
- Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Libechov 27721, Czech Republic
| | | | | | | | | | | | | |
Collapse
|
28
|
Michaelis M, Cinatl J, Cinatl J, Pouckova P, Langer K, Kreuter J, Matousek J. Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice. Anticancer Drugs 2002; 13:149-54. [PMID: 11901307 DOI: 10.1097/00001813-200202000-00006] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Bovine seminal ribonuclease (BS-RNase) is an antitumoral active enzyme exhibiting specific antitumoral action against a number of different cancer cell lines. However, its systemic use is limited by its pharmacokinetic properties and antigenicity. Therefore, it was conjugated to polyethylene glycol (PEG) chains to overcome these problems. Measurement of aspermatogenic effects of the preparation after s.c. injection and injection into the scrotum was chosen as a model for the distribution of the enzyme in the body mediated by the linkage to PEG chains. Additionally, the antigenicity of BS-RNase coupled to PEG chains (BS-RNase-PEG) was compared to that of free BS-RNase, as antigenicity is known to be one of the main obstacles in the use of protein-based drugs. BS-RNase-PEG caused aspermatogenic effects after systemic administration to mice in very low concentrations at which free BS-RNase is not effective. Moreover, BS-RNase possessed a very low antigenicity as long as it was coupled to the PEG chains. In order to investigate the antitumoral efficacy of BS-RNase-PEG in vivo, preliminary experiments on the effect of the conjugate on neuroblastoma growth in mice were performed in a UKF-NB-3 xeno-transplantate model, demonstrating a drastically increased anti-tumoral activity of the conjugate compared to the free enzyme.
Collapse
Affiliation(s)
- Martin Michaelis
- Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, 60596 Frankfurt am Main, Germany.
| | | | | | | | | | | | | |
Collapse
|
29
|
Michaelis M, Cinatl J, Vogel JU, Pouckova P, Driever PH, Cinatl J. Treatment of drug-resistant human neuroblastoma cells with cyclodextrin inclusion complexes of aphidicolin. Anticancer Drugs 2001; 12:467-73. [PMID: 11395575 DOI: 10.1097/00001813-200106000-00008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Treatment failure in most neuroblastoma (NB) patients is related to primary and/or acquired resistance to conventional chemotherapeutic agents. Aphidicolin (APH), a tetracyclic diterpene, exhibits specific cytotoxic action against NB cells. The purpose of this study was to compare antitumoral efficacy of APH in parental NB cell lines and cell subclones that exhibit drug resistance to vincristine (VCR), doxorubicin (DOX) and cisplatin. Due to poor solubility of APH in water, gamma-cyclodextrin (gamma-CD) inclusion complexes of APH were used for systemic treatment of xenotransplanted parental and VCR-resistant UKF-NB-3 tumours. APH and its gamma-CD inclusion complexes inhibited growth of parental and drug-resistant NB cells at equimolar doses in vitro. Growth of VCR-sensitive and -resistant NB tumors was inhibited at equal doses in a dose-dependent fashion in vivo. These results indicate that the specific cytotoxic activity of APH against NB cells in vitro and in vivo is independent of cellular mechanisms facilitating drug resistance to conventional chemotherapeutic drugs. Hence, taking into account our previous findings that APH acts synergistically with VCR and DOX, APH might be an additive tool for the therapy of NB and is suitable for evaluation in clinical studies of NB treatment protocols.
Collapse
Affiliation(s)
- M Michaelis
- Institut für Medizinische Virologie, Zentrum der Hygiene, Klinikum der JW Goethe-Universität, Paul-Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany
| | | | | | | | | | | |
Collapse
|
30
|
Kotchetkov R, Cinatl J, Krivtchik AA, Vogel JU, Matousek J, Pouckova P, Kornhuber B, Schwabe D, Cinatl J. Selective activity of BS-RNase against anaplastic thyroid cancer. Anticancer Res 2001; 21:1035-42. [PMID: 11396137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
BACKGROUND Anaplastic thyroid carcinoma is an aggressive solid tumor that fails to adequately respond to any known chemotherapeutic regimen. The development of effective chemotherapy agents would provide the best chance for long-term survival of patients. MATERIALS AND METHODS The cytotoxic effects of bovine seminal ribonuclease (BS-RNase) against thyroid carcinoma cell lines with different degrees of differentiation in comparison to non-malignant cells, including human foreskin fibroblasts (HFF) and retinal pigment epithelial cells (RPE), were tested using the MTT dye reduction assay. Induction of apoptosis was demonstrated by annexin V assay and expression of proteins related to apoptosis was investigated by flow cytometry. The antitumoral in vivo effects of BS-RNase were assessed on established xenografts of anaplastic thyroid carcinoma cell line 8505C in nude mice using subcutaneous injections of BS-RNase (12.5 mg/kg once a day, on 20 consecutive days). RESULTS All the tumor cell lines exhibited marked sensitivity against BS-RNase in comparison to HFF and RPE cells. The greatest growth inhibition was seen in the 8505C line, while IC50 values for papillary (B-CPAP) and poorly-differentiated thyroid carcinoma cells were about 6-fold higher. The cytotoxic action of BS-RNase was associated with induction of apoptosis. Expressions of Fas and Fas-ligand were not influenced by BS-RNase completely, while the down-regulation of Bcl-2 in treated cells was observed. In vivo treatment induced significant tumor regression after the course of 20 consecutive days. No apparent toxic effects of BS-RNase toward non-malignant cells were observed during the in vivo treatment. After cessation of therapy (day 20) tumor volume continued to decrease and the tumor was no longer detectable after 30 days of treatment induction in all animals. CONCLUSION BS-RNase may have beneficial effects for treatment of aggressive anaplastic thyroid cancer.
Collapse
Affiliation(s)
- R Kotchetkov
- Pediatric Clinic for Hematology and Oncology, University Clinics, Johann Wolfgang Goethe-University, Paul-Ehrlich Str. 40, D-60596 Frankfurt am Main, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Kotchetkov R, Cinatl J, Matousek J, Vogel J, Pouckova P, Wagner M, Kornhuber B, Schwabe D, Cinatl J. Bovine seminal ribonuclease inhibits in vivo growth of human neuroblastoma cells. Oncol Rep 2000; 7:363-7. [PMID: 10671687 DOI: 10.3892/or.7.2.363] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Bovine seminal ribonuclease (BS-RNase) is a homologue of RNase A with specific antitumor activities. It is selectively toxic for neuroblastoma (NB) cells in vitro with no significant effects on the viability of normal human cells. We evaluated the antitumoral effects of BS-RNase on human NB xenografts from UKF-NB-3 cells in athymic (nude) mice. The efficacy of direct intraneoplastic, subcutaneous and systemic delivery of BS-RNase was explored. Systemic administration of BS-RNase (12.5 mg/kg/day intraperitoneally, for 20 days in the course of four weeks) suppressed tumor growth but was not able to induce any cures. Subcutaneous injections (12.5 mg/kg/day for 20 days in the course of four weeks) and intratumoral BS-RNase treatment using the same schedule resulted in complete tumor regression. During 30 days following cessation of treatment no tumor regrowth was observed and animals were free of tumors. Toxic effects of BS-RNase (e.g., on bone marrow and inner organs) were not apparent. This data indicates that BS-RNase fulfills important criteria for a candidate antitumor agent specific for NB.
Collapse
Affiliation(s)
- R Kotchetkov
- Center of Pediatrics, Department of Hematology and Oncology, Johann-Wolfgang Goethe University Clinic, 60528 Frankfurt am Main, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Cinatl J, Cinatl J, Kotchetkov R, Pouckova P, Vogel JU, Rabenau H, Michaelis M, Kornhuber B. Cytotoxicity of L-cycloserine against human neuroblastoma and medulloblastoma cells is associated with the suppression of ganglioside expression. Anticancer Res 1999; 19:5349-54. [PMID: 10697560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
BACKGROUND Human neuroblastoma and medulloblastoma express abnormal ganglioside patterns especially GD2 and GM2 which are important for tumour growth. We tested the effects of L-cycloserine (L-CS), a potent inhibitor of synthesis of glycosphingolipids, on the growth, viability and expression of GD2 and GM2 in neuroblastoma and medulloblastoma cells. MATERIALS AND METHODS The cytotoxic effects of L-CS were tested using the MTT dye reduction assay on four neuroblastoma (IMR-32, SK-N-SH, UKF-NB-2 and UKF-NB-3), two medulloblastoma (D283 and D341) and normal human fibroblasts and epithelial cell lines. In some experiments cytotoxicity of L-CS was tested in the presence of exogenous GD2 and GM2. The expression of GD2 and GM2 was analysed by flow cytometry. The antitumoral effects of L-CS in vivo were assessed on established xenografts of UKF-NB-3 or D283 cells in athymic (nude) mice using systemic administration of the drug (150 mg/kg intraperitoneally, once per day on 20 consecutive days). RESULTS In vitro experiments revealed that L-CS was toxic for tumour cells at concentrations ranging from 0.5 to 20 micrograms/ml without any significant effects on normal fibroblasts and epithelial cells. L-CS treatment of UKF-NB-3 and D283 cells significantly inhibited expression of GD2 and GM2. The addition of exogenous GD2 and GM2 to culture medium partially prevented cytotoxic effects of L-CS on tumour cells. In vivo treatment resulted in complete tumour regression of UKF-NB-3 xenografts whereas growth of D283 xenografts was reduced by 60%. CONCLUSIONS L-CS is a selective antitumoral agent for neuroblastoma and medulloblastoma cells with the ability to reduce expression of tumour associated gangliosides. In vivo experiments suggest that L-CS may be effective drug for treatment of neuroblastoma and medulloblastoma.
Collapse
Affiliation(s)
- J Cinatl
- Zentrum der Hygiene, Institut für Medizinische Virologie, Frankfurt am Main, Germany
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Cinatl J, Cinatl J, Kotchetkov R, Vogel JU, Woodcock BG, Matousek J, Pouckova P, Kornhuber B. Bovine seminal ribonuclease selectively kills human multidrug-resistant neuroblastoma cells via induction of apoptosis. Int J Oncol 1999; 15:1001-9. [PMID: 10536185 DOI: 10.3892/ijo.15.5.1001] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Bovine seminal ribonuclease (BS-RNase) is a homologue of RNase A with specific antitumor activity. The cytotoxic action of this agent was examined in human neuroblastoma (NB) cell lines (SK-N-SH and UKF-NB-4) possessing the multidrug resistance (MDR) phenotype and NB cell lines (IMR-32, UKF-NB-1, UKF-NB-2 and UKF-NB-3) without MDR. Although MDR cells expressed large amounts of mdr-1 mRNA, contained functional P-glycoprotein and had 20- to 105-fold lower sensitivities to doxorubicin and vincristine than cells with non-MDR phenotypes, BS-RNase was equally toxic to all NB cells at concentrations employed (0.2 to 100 microg/ml). BS-RNase showed high selectivity for NB cells and was non-toxic to normal fibroblasts and epithelial cells. Ultrastructural investigation and annexin V assay showed that BS-RNase is a powerful inductor of apoptosis. The antitumoral effects of BS-RNase were also demonstrated in vivo using established subcutaneous xenografts in athymic (nude) mice of the MDR-1-bearing UKF-NB-4 cell line. Intratumoral injections (12.5 mg/kg) of BS-RNase over four weeks resulted in complete tumor regression and absence of tumor regrowth over a two-week observation period after cessation of treatment. The results show that BS-RNase selectively kills NB cells by inducing apoptosis and that this agent is active against mdr-1 expressing cells both in vitro and in vivo. BS-RNase fulfills important criteria for a candidate antitumor agent in NB patients with advanced disease.
Collapse
Affiliation(s)
- J Cinatl
- Center of Hygiene, Department of Medical Virology, Klinikum der Johann Wolfgang Goethe-Universitat, 60528 Frankfurt am Main, Germany
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Cinatl J, Cinatl J, Kotchetkov R, Driever PH, Bertels S, Siems K, Jas G, Bindseil K, Rabenau HF, Pouckova P, Doerr HW, Schwabe D. Aphidicolin glycinate inhibits human neuroblastoma cell growth in vivo. Oncol Rep 1999; 6:563-8. [PMID: 10203592 DOI: 10.3892/or.6.3.563] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Aphidicolin is a fungal derived tetracyclic diterpene antibiotic. It is selectively toxic for neuroblastoma (NB) cells in vitro but has no significant effects on the viability of normal human cells and a variety of other tumor entities. We evaluated the antitumoral effects of the water soluble ester aphidicolin glycinate (AphiG) on established human NB xenografts from UKF-NB-3 cells in athymic (nude) mice. Furthermore, we explored the efficacy of direct intraneoplastic and systemic delivery of AphiG. Systemic administration of AphiG (60 mg/kg intraperitoneally, twice per day on 10 consecutive days) significantly suppressed tumor growth but was not able to induce any cures. In contrast, intratumoral AphiG injections (60 or 40 mg/kg/twice a day for 4 days) induced complete tumor regression. Two weeks after the end of treatment no tumor cells were microscopically detectable. Animals were free of tumor for more than 90 days. Histologic examination of inner organs and bone marrow did not reveal any apparent toxic effects of AphiG. These data strongly indicate that AphiG deserves further evaluation as a specific treatment for neuroblastoma.
Collapse
Affiliation(s)
- J Cinatl
- Institut fur Medizinische Virologie, Zentrum der Hygiene, Klinikum der Johann Wolfgang Goethe-Universitat, D-60528 Frankfurt am Main, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Cinatl J, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B, Schwabe D. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997; 8:958-63. [PMID: 9436639 DOI: 10.1097/00001813-199711000-00007] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Sodium valproate (VPA) belongs to the group of simple branched-chain fatty acids and due its anticonvulsive activity is broadly applied in the treatment of epilepsy. We previously showed that VPA is able to induce cellular differentiation, to enhance immunogenicity and to inhibit proliferation of human neuroblastoma (NB) cells in vitro. Furthermore, we demonstrated that VPA inhibits proliferation, enhances neural cell adhesion molecule expression and decreases CD44 expression of human and rat glioma cells in vitro. In the present study we investigated the antitumoral effects of VPA on established human NB xenografts from UKF-NB-3 human NB cells in athymic (nude) mice. When the animals developed s.c. tumors of about 100 mm3 volume they were treated with 400 or 200 mg/kg/day VPA i.p. At the end of the treatment period (40 days) tumor volumes in animals treated with 400 and 200 mg/kg VPA were about 4- (p < 0.0001) and 2-fold (p < 0.0005) smaller than in the saline-treated control group, respectively. Histological examination of the remnant tumors of treated animals revealed induction of differentiation by induction of stroma-rich tumors and nodules that contained elongated NB cells. Pyknotic nuclei and apoptotic bodies indicated induction of apoptosis. We conclude that VPA is able to abrogate NB growth in vivo and may therefore be useful in the treatment of NB patients.
Collapse
Affiliation(s)
- J Cinatl
- Institut für Medizinische Virologie, Zentrum der Hygiene, Frankfurt, Germany
| | | | | | | | | | | | | |
Collapse
|